explore -WSS

explore

author：Wikipedia 2025-09-06 04:15:18 - browse：534

Transparent plastic divider on the reception desk in the hospital admission department with red lettering emergency. — Adobe

QuidelOrtho has recalled nearly 8,000 potentially faulty blood tests meant to help doctors quickly determine whether a patient is having a heart attack.

The tests inaccurately showed low levels of troponin, a protein that indicates damage to the heart. A false negative could lead doctors to mistakenly conclude their patient is not having a heart attack, delaying diagnosis or treatment when time is of the essence.

The device maker, which also sells products like the QuickVue Covid-19 antigen test, sent letters to health systems in May telling them to immediately stop using the test. The Food and Drug Administration classified the recall as serious, because problems with the product could result in serious injury or death. QuidelOrtho has reported 41 complaints, but no injuries or deaths so far.

The tests, which use either a blood or plasma sample, promise to return results in under half an hour. They are used in emergency rooms to triage patients suspected of having a heart attack.

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

The FDA said the patients most at risk are those with zero or abnormal heart attack symptoms, for whom a diagnosis would be easy to miss without an accurate lab test.

The company advised using a different testing method to detect heart attacks. If none are available, doctors should be extra wary of the blood panel’s readings, perform multiple tests to confirm low troponin levels, and also reference data from EKGs and other imaging.

San Diego-based QuidelOrtho said the error is due to a “raw material issue” in its recall record. The issue caused the test to falsely pick up 30% less troponin than is present. The company did not respond to STAT’s request for more information on the error.

The test maker’s last serious recall was in 2021 for reports of false negatives from its Lyra PCR Covid-19 test when used with certain lab equipment. The notice impacted more than 18,000 test kits.

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： The thinking behind the controversial eating disorder chatbot Tessa

WSS

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Senate panel passes drug pricing bills, but drops one PBM reform

Alexander Hamilton and the argument for universal insurance

Trump allegedly attempted to have surveillance video deleted: Special Counsel

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

Reanimated hearts work just as well for transplants, study finds

leisure time

explore

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

entertainment

Affirmative action in medical school literally saved lives

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

Drug repurposing or repositioning? The language matters

Moscow blames Kyiv for missile attacks in southern Russia as Kremlin forces pound Ukrainian village

The high cost of giving birth even with insurance

A public health expert passes on football's full body collisions for youths

Drug repurposing or repositioning? The language matters

Biden to sign 'historic' executive order on how US military handles sexual assault cases

Activists slam private health insurers over coverage restrictions

An outrageous hospital charge: I paid $710 for an hour of babysitting

entertainment

American Airlines has a tentative contract deal with its pilots. Southwest is still negotiating

Moscow blames Kyiv for missile attacks in southern Russia as Kremlin forces pound Ukrainian village

Altering the blood type of lungs raises potential for universal organs for transplants

Timeline: Special counsel's probe into Trump's handling of classified documents

Hospitals, health systems can help patients avoid medical debt

Biogen nominates mother of director’s child to replace him on board

explore

explore

focus

hotspot